Clovis Oncology Inc (CLVS)

Add to Watchlists
Create an Alert
24.65 +0.47  +1.94% NASDAQ Feb 22, 13:23 Delayed 2m USD
View Full Chart
CLVS Price Chart
View All Events

CLVS Events

Date Type Description
05/08/2019 16:30 EDT Misc Clovis Oncology Inc First Quarter Earnings Conference Call in 2019
05/08/2019 Earnings Clovis Oncology Inc First Quarter Earnings in 2019 Release
02/26/2019 16:30 EST Misc Clovis Oncology Inc Fourth Quarter Earnings Conference Call in 2018
02/26/2019 Earnings Clovis Oncology Inc Fourth Quarter Earnings in 2018 Release
10/30/2018 16:30 EDT Misc Clovis Oncology Inc Third Quarter Earnings Conference Call in 2018
10/30/2018 Earnings Clovis Oncology Inc Third Quarter Earnings in 2018 Release
08/01/2018 16:30 EDT Misc Clovis Oncology Inc Second Quarter Earnings Conference Call in 2018
08/01/2018 Earnings Clovis Oncology Inc Second Quarter Earnings Results in 2018
06/07/2018 Misc Clovis Oncology Inc Annual General Meeting in 2017
05/08/2018 16:30 EDT Misc Clovis Oncology Inc First Quarter Earnings Conference Call in 2018
View All Performance Charts

CLVS Total Returns Comparison

Advertisement

CLVS One Page Reports

Edit

Profile

  • URL: http://www.clovisoncology.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-IRHome
  • HQ State/Province: Colorado
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Feb. 26, 2019
  • Last Earnings Release: Oct. 30, 2018
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

CLVS Comparables

Edit

CLVS Excel Add-In Codes

  • Name: =YCI("CLVS","name")
  • Description: =YCI("CLVS","description")
  • Sector: =YCI("CLVS","sector")
  • Industry: =YCI("CLVS","industry")
  • Est. Current Fiscal Year End: =YCI("CLVS","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.